ADIL - EXCLUSIVE: Adial Pharma Announces Key Patent To Combine Genetic Diagnostic With Lead Drug For Alcohol Addiction | Benzinga
Adial Pharmaceuticals Inc (NASDAQ: ADIL) has been awarded a key patent combining the use of the company's proprietary genetic diagnostic to detect select genotypes for genetically targeted treatment of alcohol use disorder (AUD) and opioid use disorder (OUD) with the company's lead investigational product AD04.
AD04 is a genetically targeted, serotonin-3 receptor antagonist therapeutic agent for Alcohol ...